ASCO: BMS hails “compelling” phase 3 celmod readout

Pharmaphorum

Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.

pharminent May 29, 2026 (Last updated: May 29, 2026)

Pharmaphorum

Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.

Related Stories